A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2023-09-07
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-26 (study day 35); relationship: Y
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 59); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-25 (study day 126); relationship: not assessed
mild
assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-04-06 (study day 198); relationship: not assessed
Data queries
No data queries.